Avandia's TIDE May Come In Smaller
This article was originally published in The Pink Sheet Daily
Executive Summary
Two advisory panels recommended that FDA allow the trial of GlaxoSmithKline's Avandia (rosiglitazone) to continue but questioned its design, providing important hints for drug companies planning post-marketing safety trials in the future.